Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)

Status
Enrolling By Invitation
Cancer Type
Leukemia
Trial Phase
Phase III
Eligibility
, Male and Female
Study Type
Treatment
NCT ID
NCT02656303
Protocol IDs
UTX-TGR-304 (primary)
Study Sponsor
TG Therapeutics, Inc
NCI Full Details

Objectives

Primary

To establish that the combination of ublituximab + TGR-1202 is superior to the combination of obinutuzumab + chlorambucil as measured by duration of progressive free survival

 

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a state-supported nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education to improve cancer care for Georgians in rural, urban, and suburban communities across the state.